M&A Deal Summary

Oncternal Therapeutics Acquires GTx

On March 7, 2019, Oncternal Therapeutics acquired life science company GTx

Acquisition Highlights
  • This is Oncternal Therapeutics’ 1st transaction in the Life Science sector.
  • This is Oncternal Therapeutics’ 1st transaction in the United States.
  • This is Oncternal Therapeutics’ 1st transaction in Tennessee.

M&A Deal Summary
Date 2019-03-07
Target GTx
Sector Life Science
Buyer(s) Oncternal Therapeutics
Deal Type Merger
Advisor(s) Aquilo Partners LP (Financial)
Cooley (Legal)

Target

GTx

Memphis, Tennessee, United States
GTx is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. GTx was founded in 1997 and is based in Memphis, Tennessee.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Oncternal Therapeutics

San Diego, California, United States
Category Company
Founded 2013
Sector Life Science
DESCRIPTION

Oncternal Therapeutics, Inc. is a clinical-stage oncology company developing novel, potential first-in-class therapeutic candidates for cancers with a critical unmet medical need. Oncternal Therapeutics was founded in 2013 and is based in San Diego, California.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Merger) 1 of 1
State (Tennessee) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1
Mergr

Product

Company

Legal